A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI).

Trial Profile

A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs Daptomycin; Daptomycin; Teicoplanin; Teicoplanin; Vancomycin; Vancomycin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jul 2012 Trial phase changed from IV to III, actual patient number changed from 280 to 194 and additional trial locations added as reported by ClinicalTrials.gov.
    • 10 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Results from this trial have been presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top